Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Albumin use in patients with septic shock-Post-hoc analyses of an international randomised fluid trial

TS. Meyhoff, A. Granholm, PB. Hjortrup, P. Sivapalan, T. Lange, JH. Laake, M. Cronhjort, SM. Jakob, M. Cecconi, M. Nalos, M. Ostermann, MLNG. Malbrain, MH. Møller, A. Perner

. 2024 ; 68 (3) : 372-384. [pub] 20231117

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006981

BACKGROUND: Albumin administration is suggested in patients with sepsis and septic shock who have received large volumes of crystalloids. Given lack of firm evidence, clinical practice variation may exist. To address this, we investigated if patient characteristics or trial site were associated with albumin use in septic shock. METHODS: We conducted a post-hoc study of the CLASSIC international, randomised clinical trial of fluid volumes in septic shock. Associations between selected baseline variables and trial site with albumin use during ICU stay were assessed in Cox models considering death, ICU discharge, and loss-to-follow-up as competing events. Baseline variables were first assessed individually, adjusted for treatment allocation (restrictive vs. standard IV fluid), and then adjusted for allocation and the other baseline variables. Site was assessed in a model adjusted for allocation and baseline variables. RESULTS: We analysed 1541 of 1554 patients randomised in CLASSIC (99.2%). During ICU stay, 36.3% of patients in the restrictive-fluid group and 52.6% in the standard-fluid group received albumin. Gastrointestinal focus of infection and higher doses of norepinephrine were most strongly associated with albumin use (subgroup with highest quartile of norepinephrine doses, hazard ratio (HR) 2.58, 95% CI 1.89 to 3.53). HRs for associations between site and albumin use ranged from 0.11 (95% CI 0.05 to 0.26) to 1.70 (95% CI 1.06 to 2.74); test for overall effect of site: p < .001. CONCLUSIONS: In adults with septic shock, gastrointestinal focus of infection and higher doses of norepinephrine at baseline were associated with albumin use, which also varied substantially between sites.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006981
003      
CZ-PrNML
005      
20240423155626.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/aas.14359 $2 doi
035    __
$a (PubMed)37975538
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Meyhoff, Tine Sylvest $u Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $1 https://orcid.org/0000000218401596
245    10
$a Albumin use in patients with septic shock-Post-hoc analyses of an international randomised fluid trial / $c TS. Meyhoff, A. Granholm, PB. Hjortrup, P. Sivapalan, T. Lange, JH. Laake, M. Cronhjort, SM. Jakob, M. Cecconi, M. Nalos, M. Ostermann, MLNG. Malbrain, MH. Møller, A. Perner
520    9_
$a BACKGROUND: Albumin administration is suggested in patients with sepsis and septic shock who have received large volumes of crystalloids. Given lack of firm evidence, clinical practice variation may exist. To address this, we investigated if patient characteristics or trial site were associated with albumin use in septic shock. METHODS: We conducted a post-hoc study of the CLASSIC international, randomised clinical trial of fluid volumes in septic shock. Associations between selected baseline variables and trial site with albumin use during ICU stay were assessed in Cox models considering death, ICU discharge, and loss-to-follow-up as competing events. Baseline variables were first assessed individually, adjusted for treatment allocation (restrictive vs. standard IV fluid), and then adjusted for allocation and the other baseline variables. Site was assessed in a model adjusted for allocation and baseline variables. RESULTS: We analysed 1541 of 1554 patients randomised in CLASSIC (99.2%). During ICU stay, 36.3% of patients in the restrictive-fluid group and 52.6% in the standard-fluid group received albumin. Gastrointestinal focus of infection and higher doses of norepinephrine were most strongly associated with albumin use (subgroup with highest quartile of norepinephrine doses, hazard ratio (HR) 2.58, 95% CI 1.89 to 3.53). HRs for associations between site and albumin use ranged from 0.11 (95% CI 0.05 to 0.26) to 1.70 (95% CI 1.06 to 2.74); test for overall effect of site: p < .001. CONCLUSIONS: In adults with septic shock, gastrointestinal focus of infection and higher doses of norepinephrine at baseline were associated with albumin use, which also varied substantially between sites.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a septický šok $x farmakoterapie $x komplikace $7 D012772
650    12
$a sepse $x farmakoterapie $x etiologie $7 D018805
650    _2
$a noradrenalin $x terapeutické užití $7 D009638
650    _2
$a albuminy $x terapeutické užití $7 D000418
650    _2
$a tekutinová terapie $x škodlivé účinky $7 D005440
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Granholm, Anders $u Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $1 https://orcid.org/0000000157997655
700    1_
$a Hjortrup, Peter Buhl $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $u Department of Cardiothoracic Anaesthesia and Intensive Care, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Sivapalan, Praleene $u Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $1 https://orcid.org/0000000204420032
700    1_
$a Lange, Theis $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $u Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Laake, Jon Henrik $u Department of Anaesthesiology and Intensive Care Medicine, Rikshospitalet, Oslo University Hospital, Norway $u Division of Emergencies and Critical Care, Rikshospitalet, Oslo University Hospital, Norway
700    1_
$a Cronhjort, Maria $u Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Jakob, Stephan M $u University of Bern, Bern, Switzerland
700    1_
$a Cecconi, Maurizio $u Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy $u Department of Anaesthesia and Intensive Care Medicine, IRCCS Humanitas Research Hospital, Rozzano, Italy
700    1_
$a Nalos, Marek $u Medical Intensive Care Unit 1, Interni klinika, Fakultni Nemocnice, Plzen, Czech Republic
700    1_
$a Ostermann, Marlies $u Department of Intensive Care, Guy's and St Thomas' Hospital, London, UK
700    1_
$a Malbrain, Manu L N G $u Department of Intensive Care Medicine, University Hospital Brussels (UZB), Jette, Belgium $u First Department of Anaesthesiology and Intensive Therapy, Medical University of Lublin, Lublin, Poland $1 https://orcid.org/0000000218165255
700    1_
$a Møller, Morten Hylander $u Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Perner, Anders $u Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark $u Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
773    0_
$w MED00000016 $t Acta anaesthesiologica Scandinavica $x 1399-6576 $g Roč. 68, č. 3 (2024), s. 372-384
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37975538 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155622 $b ABA008
999    __
$a ok $b bmc $g 2081145 $s 1216748
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 68 $c 3 $d 372-384 $e 20231117 $i 1399-6576 $m Acta anaesthesiologica Scandinavica $n Acta Anaesthesiol Scand $x MED00000016
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace